###begin article-title 0
Neuroprotective Effects of the Triterpenoid, CDDO Methyl Amide, a Potent Inducer of Nrf2-Mediated Transcription
###end article-title 0
###begin p 1
Conceived and designed the experiments: LY MFB. Performed the experiments: LY NC BT RKC MK EJW KTL CW DR RR ESM JDM MBS MFB. Analyzed the data: LY NC JDM MBS MFB. Contributed reagents/materials/analysis tools: JDM MBS MFB. Wrote the paper: LY MFB.
###end p 1
###begin p 2
###xml 1051 1052 1051 1052 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 618 623 <span type="species:ncbi:10090">mouse</span>
###xml 846 850 <span type="species:ncbi:10090">mice</span>
###xml 887 891 <span type="species:ncbi:10116">rats</span>
The NF-E2-related factor-2 (Nrf2)/antioxidant response element (ARE) signaling pathway regulates phase 2 detoxification genes, including a variety of antioxidative enzymes. We tested neuroprotective effects of the synthetic triterpenoid CDDO-MA, a potent activator of the Nrf2/ARE signaling. CDDO-MA treatment of neuroblastoma SH-SY5Y cells resulted in Nrf2 upregulation and translocation from cytosol to nucleus and subsequent activation of ARE pathway genes. CDDO-MA blocked t-butylhydroperoxide-induced production of reactive oxygen species (ROS) by activation of ARE genes only in wild type, but not Nrf2 knockout mouse embryonic fibroblasts. Oral administration of CDDO-MA resulted in significant protection against MPTP-induced nigrostriatal dopaminergic neurodegeneration, pathological alpha-synuclein accumulation and oxidative damage in mice. Additionally, CDDO-MA treatment in rats produced significant rescue against striatal lesions caused by the neurotoxin 3-NP, and associated increases in the oxidative damage markers malondialdehyde, F2-Isoprostanes, 8-hydroxy-2-deoxyguanosine, 3-nitrotyrosine, and impaired glutathione homeostasis. Our results indicate that the CDDO-MA renders its neuroprotective effects through its potent activation of the Nrf2/ARE pathway, and suggest that triterpenoids may be beneficial for the treatment of neurodegenerative diseases like Parkinson's disease and Huntington's disease.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 223 226 223 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Lin1">[1]</xref>
###xml 228 231 228 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Browne1">[2]</xref>
###xml 376 379 376 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Lee1">[3]</xref>
###xml 380 383 380 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Calkins1">[6]</xref>
###xml 1042 1045 1042 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Holtzclaw1">[7]</xref>
###xml 1047 1050 1047 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Kobayashi1">[8]</xref>
###xml 1272 1275 1272 1275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-DinkovaKostova1">[9]</xref>
###xml 1276 1280 1276 1280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Liby1">[12]</xref>
###xml 1430 1434 1430 1434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Kwak1">[13]</xref>
There is increasing evidence showing that both mitochondrial dysfunction and oxidative damage play a key role in the pathogenesis of neurodegenerative diseases such as Parkinson's disease (PD) and Huntington's disease (HD) [1], [2]. An extremely promising pathway for neurotherapeutics is the NF-E2-related factor-2 (Nrf2)/antioxidant response element (ARE) signaling pathway [3]-[6]. The transcription factor Nrf2 is a key regulatory factor in the coordinated induction of a battery of cytoprotective genes, including those encoding for both antioxidant and anti-inflammatory proteins. The induction of these protective genes depends on the nuclear translocation of Nrf2 and its binding to the ARE, a regulatory enhancer sequence, which is present in the promoter region of the involved genes. The regulation of the Nrf system involves another cytosolic protein, KEAP1 (kelch-like ECH-associated protein 1), which binds to Nrf2 in the cytosol and prevents its nuclear translocation and subsequent transcriptional activation of the ARE genes [7], [8]. Critical cysteine residues in the KEAP1 protein are essential for its ability to inactivate Nrf2 by retaining it in the cytosol. These cysteine residues are targets for various drugs that form Michael adducts with KEAP1 [9]-[12]. Nrf2/ARE signaling regulates over 200 genes, including those encoding anti-oxidative genes and detoxifying enzymes (known as the "phase 2" enzymes) [13].
###end p 4
###begin p 5
###xml 237 239 237 239 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 244 246 244 246 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 511 515 511 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Dore1">[14]</xref>
###xml 566 570 566 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Ryter1">[15]</xref>
###xml 733 737 733 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Khor1">[16]</xref>
###xml 841 845 841 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Liberatore1">[17]</xref>
###xml 847 851 847 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Teismann1">[18]</xref>
###xml 769 773 <span type="species:ncbi:10090">mice</span>
###xml 823 828 <span type="species:ncbi:10090">mouse</span>
One critical enzyme that is induced by the Nrf2 signaling pathway is NADPH quinone oxidoreductase-1 (NQO-1). This enzyme is involved in detoxification of protein-bound quinone, and it functions to maintain alpha-tocopherol and coenzyme Q10 (CoQ10) in their reduced antioxidant states. Another ARE-dependent protein is the stress responsive inducible enzyme hemeoxygenase-1 (HO-1). HO-1 is involved in the metabolism of the prooxidant heme to the antioxidant pigment biliverdin, ferrous iron and carbon monoxide [14], and it has profound anti-inflammatory properties [15]. Two inflammatory mediators which are downregulated by Nrf2 are inducible nitric oxide synthase (iNOS) and the prostaglandin synthesizing cyclooxygenase 2 (COX2) [16]. Both iNOS- and COX2-deficient mice are resistant to dopaminergic neurotoxicity in a mouse model of PD [17], [18].
###end p 5
###begin p 6
###xml 196 200 196 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Lee2">[19]</xref>
###xml 479 483 479 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Shih1">[20]</xref>
###xml 620 624 620 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Calkins2">[21]</xref>
###xml 843 847 843 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Chen1">[22]</xref>
###xml 849 853 849 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Vargas1">[23]</xref>
###xml 32 36 <span type="species:ncbi:10090">mice</span>
###xml 101 105 <span type="species:ncbi:10090">mice</span>
###xml 243 246 <span type="species:ncbi:10116">rat</span>
###xml 412 416 <span type="species:ncbi:10090">mice</span>
###xml 626 641 <span type="species:ncbi:10090">Transgenic mice</span>
###xml 748 753 <span type="species:ncbi:10090">mouse</span>
Experiments using Nrf2 knockout mice and primary astroglial and neuronal cultures derived from these mice show that disruption of Nrf2 renders neuronal tissue more susceptible to oxidative stress [19]. Conversely, Nrf2 overexpression in mixed rat neuron-glia cortical cultures enhances antioxidant capacity in both neuronal and astroglial cells, and protects cortical neurons from excitotoxicity. Nrf2 deficient mice are more susceptible to 3-nitropropionic acid (3-NP) toxicity [20]. Transplantation of Nrf2 overexpressing astrocytes protects against the toxic effects of the mitochondrial complex 2 inhibitor malonate [21]. Transgenic mice over-expressing Nrf2 in astrocytes are resistant to MPTP neurotoxicity and when crossed into a transgenic mouse model of amyotrophic lateral sclerosis they delayed disease onset and prolonged survival [22], [23].
###end p 6
###begin p 7
###xml 593 596 593 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-DinkovaKostova1">[9]</xref>
###xml 598 602 598 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Suh1">[24]</xref>
###xml 603 607 603 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Yates2">[29]</xref>
###xml 768 771 768 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-DinkovaKostova1">[9]</xref>
###xml 858 859 858 859 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 917 924 917 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005757-g001">Fig. 1A</xref>
###xml 1079 1082 1079 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-DinkovaKostova1">[9]</xref>
###xml 1084 1088 1084 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Honda1">[25]</xref>
###xml 1232 1239 1232 1239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1264 1267 1264 1267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-DinkovaKostova1">[9]</xref>
###xml 1269 1273 1269 1273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Liby2">[26]</xref>
###xml 1275 1279 1275 1279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Thimmulappa1">[28]</xref>
###xml 1361 1366 <span type="species:ncbi:10090">mouse</span>
There is, therefore, an excellent rationale for the development of new neuroprotective agents, based on their ability to enhance activity of Nrf2. Oleanolic acid is a naturally occurring triterpenoid, which has been used for centuries in Asian medicine, due to its anti-inflammatory activity. Synthetic triterpenoids such as CDDO have been found to be potent inducers of the transcriptional activity of Nrf2, resulting in marked induction of NQO-1, HO-1, glutathione transferases, and other cytoprotective enzymes, as well as suppressing induction of iNOS and COX2 at nanomolar concentrations [9], [24]-[29]. One of the possible mechanisms of these triterpenoids as Nrf2 inducers is their involvement in Michael reaction to reactive cysteine residues on KEAP1 protein [9]. In the present study, we used the synthetic triterpenoid, CDDO-methyl amide (2-cyano-N-methyl-3,12-dioxooleana-1,9(11)-dien-28 amide; CDDO-MA) (Fig. 1A), which is at least 200,000 times more potent than its naturally occurring distant parent, oleanolic acid, as an inducer of NQO-1 or a suppressor of iNOS [9], [25]. The cytoprotective activity of these triterpenoids is dependent on activation of Nrf2, since such activity is lost, both in cell cultures and in vivo, in the absence of Nrf2 [9], [26], [28]. Furthermore, pharmacodynamically meaningful levels of CDDO-MA are achievable in mouse brain after oral dosing, in contrast to its immediate carboxylic acid parent, CDDO, which has poor penetration of the blood-brain barrier.
###end p 7
###begin title 8
CDDO-MA treatment to SH-SY5Y cells causes Nrf2 translocation to nucleus and subsequent activation of ARE pathway.
###end title 8
###begin p 9
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A.</italic>
###xml 317 319 317 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B.</italic>
###xml 693 695 685 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C.</italic>
###xml 1060 1061 1050 1051 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 1112 1120 1102 1110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D and E.</italic>
###xml 1515 1516 1503 1504 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 1567 1569 1555 1557 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F.</italic>
###xml 1830 1831 1816 1817 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
A. Chemical structures of oleanolic acid and CDDO-MA. Oleanolic acid is a naturally occurring triterpenoid with structural similarities to CDDO. CDDO that is over 200,000 times more potent than the parent oleanolic acid was chemically modified by addition of a methyl group to obtain increased brain bioavailability. B. SH-SY5Y neuroblastoma cells were treated with CDDO-MA (1 microM) or DMSO as a control. In DMSO controls Nrf2 is localized to cytosol as immunostained by anti-Nrf2 antibody (closed arrow) with DAPI (open arrow) a nuclear stain. After 8 hours of CDDO-MA treatment Nrf2 from cytosol translocates to the nucleus and colocalizes with DAPI (straight arrow), Scale bar 12 microm. C. Nuclear translocation of Nrf2 results in a significant increase in mRNA levels of Nrf2 and other ARE genes such as NQO-1, glutathione reductase (GR) and HO-1 measured by RT-PCR at 8 and 24 hours after drug treatment. Data represented as Mean+/-SEM showing relative levels of mRNA at various time points compared to DMSO controls, **p<0.05 and ***p<0.001. Students-t test, n = 5 samples for each experimental groups. D and E. Increases in mRNA levels of Nrf2 and ARE genes showed corresponding increases in levels of their respective proteins analyzed by western blotting and densitometry at 8 and 24 hours after CDDO-MA treatment. Data represented as Mean+/-SEM showing relative percent change in levels of protein normalized to actin at various time points compared to DMSO controls, **p<0.05 and ***p<0.001. Students-t test, n = 6 samples for each experimental groups. F. CDDO-MA treatment resulted in a significant dose-response increase in levels of reduced glutathione (GSH) measured at 24 hours. Data represented as Mean+/-SEM showing GSH levels at 24 hours compared to DMSO controls, **p<0.05 and ***p<0.001 following Students t-test (n = 6). Values represented as nanomoles/mg protein from total cell lysate.
###end p 9
###begin p 10
In the present study, we found that CDDO-MA is a very potent and selective activator of the neuroprotective Nrf2/ARE pathway. Furthermore, due to its ability to activate the Nrf2 pathway, CDDO-MA exerts profound neuroprotective effects against MPTP and 3-NP neurotoxicity. We show that the neuroprotective effects observed are due to its antioxidant effects, caused by induction of pathways known to be regulated through Nrf2/ARE, such as glutathione synthesis. This is the first report to show that a synthetic oleanane triterpenoid can be neuroprotective in experimental models of PD and HD, and has potential therapeutic implications for the treatment of these disabling illnesses.
###end p 10
###begin title 11
Results
###end title 11
###begin title 12
CDDO-MA causes Nrf2 upregulation and nuclear translocation to activate the ARE pathway
###end title 12
###begin p 13
###xml 129 132 129 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-DinkovaKostova1">[9]</xref>
###xml 134 138 134 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Liby2">[26]</xref>
###xml 140 144 140 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Thimmulappa1">[28]</xref>
###xml 614 623 606 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005757-g001">Figure 1B</xref>
###xml 1060 1067 1044 1051 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005757-g001">Fig. 1C</xref>
###xml 1282 1295 1266 1279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005757-g001">Fig. 1D and E</xref>
###xml 1731 1738 1715 1722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005757-g001">Fig. 1F</xref>
###xml 1966 1973 1946 1953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005757-g001">Fig. 1F</xref>
Previous studies have demonstrated that synthetic triterpenoids activate Nrf2 mediated ARE transcription in non-neuronal systems [9], [26], [28]. We studied the ability of CDDO-MA to activate this pathway in a neuronal cell line. SH-SY5Y neuroblastoma cells were treated with various doses of CDDO-MA (0.5-2 microM) or DMSO as control and analyzed for cellular localization of Nrf2 at different time points. After 8 hours of CDDO-MA (1 microM) treatment Nrf2 from cytosol translocated to nucleus as evidenced by its colocalization with the nuclear dye DAPI while Nrf2 was retained in the cytosol in DMSO controls (Figure 1B). Nuclear translocation of Nrf2 from cytosol was also observed at 8 hours following CDDO-MA at doses of 0.5 and 2 microM (data not shown). Nuclear translocation of Nrf2 following CDDO-MA (1 microM) treatment resulted in significant (0.5-4.5 fold) increases in mRNA levels of Nrf2 and other ARE genes such as NQO-1, glutathione reductase (GR) and hemeoxygenase-1 (HO-1) as measured by RT-PCR at 8 and 24 hours compared to DMSO controls (Fig. 1C). Increases in mRNA levels of Nrf2 and ARE genes showed corresponding (0.5-4.8 fold) increase in levels of their proteins at 24 hours after CDDO-MA treatment determined by immunoblotting and densitometry analyses (Fig. 1D and E). Protein levels of glutathione reductase were markedly increased even at 8 hours of CDDO-MA treatment. This upregulation of glutathione reductase mRNA and its protein levels following CDDO-MA treatment resulted in a dose-dependent increase in levels of reduced glutathione (GSH), a non-significant decrease of oxidized glutathione (GSSG) and a significant increase in the GSH/GSSG ratio measured in the total cell lysate at 24 hours (Fig. 1F). The increase in GSH levels and the ratio (GSH/GSSG) were dose-dependently increased with doses of 0.5-2 microM CDDO-MA. These doses resulted in Nrf2 upregulation, its nuclear translocation, and activation of the ARE pathway (Fig. 1F and data not shown).
###end p 13
###begin title 14
Activation of Nrf2/ARE pathway by CDDO-MA is Nrf2 dependent.
###end title 14
###begin p 15
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A.</italic>
###xml 528 529 526 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 616 618 614 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B.</italic>
###xml 41 46 <span type="species:ncbi:10090">mouse</span>
###xml 647 652 <span type="species:ncbi:10090">mouse</span>
A. Wild type (WT) and Nrf2 knockout (KO) mouse embryonic fibroblasts were pretreated with either CDDO-MA (1, 10 and 100 nM) or DMSO (as control) for 18 hours. Analysis of ARE genes showed a statistically significant increase in GSTa3, HO-1 and NQO-1 in wild type fibroblasts compared to DMSO treated controls. Nrf2 knockout fibroblasts failed to induce ARE genes following treatment with CDDO-MA compared to respective DMSO controls, implicating that CDDO-MA requires Nrf2 to activate ARE signaling. Data represent mean+/-SEM, *P<0.001 when compared with the controls, by ANOVA, n = 3 from two separate experiments. B. Wild type and Nrf2 knockout mouse embryonic fibroblasts were pretreated with either CDDO-MA (1, 10 and 100 nM) or DMSO (as control) for 18 hours. The next day, 250 microM tert-butyl hydroperoxide was added to these fibroblasts for 15 minutes, and generation of ROS was measured by flow cytometry. CDDO-MA treatment resulted in a significant dose dependent reduction of tBHP-induced ROS generation in wild type fibroblasts. Nrf2 knockout fibroblasts failed to show reduction in tBHP-induced ROS generation. *p<0.05 compared to knockout fibroblasts; #p<0.05 compared to 1 nM CDDO-MA, by ANOVA, n = 3 from two separate experiments.
###end p 15
###begin title 16
CDDO-MA activates the ARE pathway in an Nrf2-dependent manner and blocks t-butylhydroperoxide-induced ROS generation
###end title 16
###begin p 17
###xml 177 181 177 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Leung1">[30]</xref>
###xml 571 578 571 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005757-g002">Fig. 2A</xref>
###xml 1398 1405 1398 1405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005757-g002">Fig. 2B</xref>
###xml 111 116 <span type="species:ncbi:10090">mouse</span>
###xml 172 176 <span type="species:ncbi:10090">mice</span>
###xml 850 855 <span type="species:ncbi:10090">mouse</span>
To determine if the activation of ARE pathway by CDDO-MA is through the Nrf2-mediated transcription we studied mouse embryonic fibroblasts from wild type and Nrf2 knockout mice [30]. Following overnight treatment of CDDO-MA (100 nM) or DMSO in wild type and Nrf2 knockout fibroblasts, analysis of mRNA levels for the ARE genes such as glutathione S-transferase alpha 3 (GSTa3), HO-1 and NQO-1 were studied using RT-PCR. RT-PCR analyses of these ARE activated genes showed significant 5-6 fold inductions in wild type fibroblast cells, but not in the Nrf2 knockout cells (Fig. 2A). This suggests that indeed the ARE activation caused by CDDO-MA is through Nrf2 mediated transcription. Furthermore at a functional level we tested the ability of CDDO-MA to block t-butylhydroperoxide generated reactive oxygen species (ROS). Wild type and Nrf2 knockout mouse embryonic fibroblasts were pre-treated overnight with either CDDO-MA (1, 10, and 100 nM) or DMSO. The next day, cells were loaded with a fluorescent indicator for 30 minutes and then challenged with 250 uM t-butylhydroperoxide (a potent oxidant known to generate toxic free radicals) for 15 minutes. CDDO-MA treatment blocked t-butylhydroperoxide-induced ROS generation in wild type fibroblast cells in a dose-dependent manner, but there were no effects of CDDO-MA on t-butylhydroperoxide-induced ROS generation in Nrf2 knockout fibroblasts (Fig. 2B). CDDO-MA is, therefore, a potent and selective activator of the Nrf2/ARE pathway and can scavenge t-butylhydroperoxide-induced ROS generation through the induction of phase 2 detoxifying ARE genes only in the presence of Nrf2.
###end p 17
###begin title 18
###xml 30 35 <span type="species:ncbi:10090">mouse</span>
Bioavailability of CDDO-MA in mouse brain
###end title 18
###begin p 19
###xml 68 76 68 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 550 557 550 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005757-g001">Fig. 1A</xref>
###xml 854 857 854 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-DinkovaKostova1">[9]</xref>
###xml 859 863 859 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Honda1">[25]</xref>
###xml 1007 1013 1007 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005757-g003">Fig. 3</xref>
###xml 109 113 <span type="species:ncbi:10090">mice</span>
###xml 271 276 <span type="species:ncbi:10090">mouse</span>
###xml 599 603 <span type="species:ncbi:10090">mice</span>
###xml 977 981 <span type="species:ncbi:10090">mice</span>
Due to its ability to activate the neuroprotective Nrf2/ARE pathway in vitro we then administered CDDO-MA to mice in order to test the neuroprotective efficacy of ARE activation in animal models of neurodegeneration. CDDO-MA achieves meaningful pharmacological levels in mouse brain in contrast to the naturally occurring parent oleanolic acid when administered by diet. The improved brain penetration of CDDO-MA was achieved by chemical modification of the parent oleanolic acid by replacing the carboxylic acid residue with the methyl amide group (Fig. 1A). In three separate experiments in which mice were fed CDDO-MA in the diet (800 mg/kg of diet), mass spectrometry analysis showed brain tissue levels ranging from 60-120 nM, a level associated with marked induction of phase 2 enzymes and suppression of iNOS and COX-2 in cell culture experiments [9], [25]. The dose we selected for these experiments (800 mg/kg of diet) gave brain levels that were twice those found in mice fed only 400 mg/kg diet (Fig. 3).
###end p 19
###begin title 20
###xml 36 40 <span type="species:ncbi:10090">mice</span>
Brain bioavailability of CDDO-MA in mice.
###end title 20
###begin p 21
###xml 289 293 <span type="species:ncbi:10090">mice</span>
CDDO-MA shows pharmacodynamically meaningful levels in brain. A dose-dependent increase in concentration of CDDO-MA was observed using an LC-MS analysis of acetonitrile brain extracts measured following administration CDDO-MA (at 200, 400 and 800 mg/kg of rodent diet) for one week, n = 5 mice per group. Vehicle diet consisting of 1:3 (ethanol:Neobee oil) showed no CDDO-MA levels in brain (data not shown).
###end p 21
###begin title 22
CDDO-MA attenuates MPTP-induced nigrostriatal dopaminergic neurodegeneration
###end title 22
###begin p 23
###xml 744 751 744 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005757-t001">Table 1</xref>
###xml 1104 1111 1104 1111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005757-g004">Fig. 4A</xref>
###xml 1321 1328 1321 1328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005757-g004">Fig. 4B</xref>
###xml 144 148 <span type="species:ncbi:10090">Mice</span>
We examined whether the ability of CDDO-MA to activate Nrf2/ARE signaling is beneficial in an experimental animal model of Parkinson's disease. Mice were administered either CDDO-MA (800 mg/kg of diet) or control rodent diet for 7 days before MPTP (10 mg/kg, i.p. 3 doses every 2 hours in one day) and then for 7 days after MPTP. One week following the last MPTP treatment, there was a profound reduction (about 80%) in total striatal dopamine and also its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA) as compared to phosphate-buffered saline (PBS) controls. CDDO-MA treatment significantly attenuated MPTP-induced striatal depletion of dopamine and its metabolites as compared to the MPTP group on control diet (Table 1) (ANOVA, p<0.01). Immunohistochemical analysis of dopaminergic neurons of the substantia nigra pars compacta (SNpc) showed a profound loss of tyrosine hydroxylase (TH)-immunoreactivity 7 days after acute MPTP as compared to PBS controls. CDDO-MA treatment significantly protected against the loss of TH-immunoreactive dopaminergic neurons in the SNpc (Fig. 4A). Counts of total neurons (Nissl positive) and TH-immunopositive neurons in the SNpc showed that treatment with CDDO-MA significantly reduced the MPTP-induced loss of both total and TH-immunopositive neurons (Fig. 4B) (ANOVA, p<0.05).
###end p 23
###begin title 24
CDDO-MA attenuates MPTP-induced nigrostriatal dopaminergic neurodegeneration.
###end title 24
###begin p 25
###xml 306 307 306 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 536 538 536 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B.</italic>
###xml 783 785 783 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C.</italic>
###xml 1016 1018 1016 1018 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D.</italic>
###xml 1286 1287 1286 1287 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">#</sup>
###xml 1287 1288 1287 1288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1327 1328 1327 1328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1388 1390 1388 1390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E.</italic>
###xml 1706 1708 1706 1708 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F.</italic>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 374 378 <span type="species:ncbi:10090">mice</span>
###xml 852 856 <span type="species:ncbi:10090">mice</span>
###xml 1270 1274 <span type="species:ncbi:10090">mice</span>
###xml 1476 1480 <span type="species:ncbi:10090">mice</span>
###xml 1686 1690 <span type="species:ncbi:10090">mice</span>
###xml 1782 1786 <span type="species:ncbi:10090">mice</span>
###xml 2117 2121 <span type="species:ncbi:10090">mice</span>
Mice were pre-treated with either CDDO-MA or control diet 7 days before acute (MPTP 10 mg/kg, i.p. 3 doses every 2 hours in one day) and chronic (MPTP 40 mg/kg, for 28 day through continuous subcutaneous infusion using mini-osmotic pumps) MPTP treatment. Control animals received identical volumes of PBS. A Photomicrographs of TH-immunostained sections through the SNpc of mice on acute MPTP show a significant reduction in TH-positive neurons of SNpc. CDDO-MA treatment significantly blocked MPTP-induced loss of TH-positive neurons. B. Consistent with TH-immunostaining of SNpc, stereologic cell counts of total (Nissl-positive) and TH-immunopositive neurons of SNpc showed a significant loss following MPTP administration which was significantly attenuated by CDDO-MA treatment. C. Photomicrographs of TH-immunostained sections through the SNpc of mice on chronic MPTP show a significant reduction in TH-positive neurons of SNpc. CDDO-MA treatment significantly blocked MPTP-induced loss of TH-positive neurons. D. Consistent with TH-immunostaining of SNpc, stereologic cell counts of total (Nissl-positive) and TH-immunopositive neurons of SNpc showed a significant loss following MPTP administration which was significantly attenuated by CDDO-MA treatment. n = 10 mice per group. #p<0.05 compared to control diet alone; *P<0.05 when compared with the control diets with MPTP group. E. Photomicrographs of malondialdehyde (MDA)-immunostained sections through the SNpc of mice on chronic MPTP show a significant increase of MDA staining in SNpc of MPTP treated animals. CDDO-MA treatment resulted in a marked reduction of MPTP-induced MDA formation. Representative image from n = 5 mice in each group. F. Photomicrographs of alpha-synuclein stained sections through the SNpc of mice on chronic MPTP show a significant increase of alpha-synuclein accumulation in SNpc of MPTP treated animals. CDDO-MA treatment resulted in a significant reduction of MPTP-induced alpha-synuclein accumulation in SNpc neurons. High magnification inserts show the alpha-synuclein staining in neurons. Representative image from n = 5 mice in each group.
###end p 25
###begin title 26
Neuroprotective effects of CDDO-MA on striatal dopamine and its metabolites in MPTP neurotoxicity.
###end title 26
###begin p 27
Data are expressed as mean+/-SEM. Values represent as ng per mg protein.
###end p 27
###begin p 28
#, p<0.05, ##, p<0.01compared to PBS groups; *, p<0.05, **, p<0.01 compared to control diet +MPTP group, ANOVA, Student-Newman-Keul's post test.
###end p 28
###begin p 29
###xml 148 152 148 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Fornai1">[31]</xref>
###xml 154 158 154 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Thomas2">[32]</xref>
###xml 752 759 752 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005757-t001">Table 1</xref>
###xml 1050 1063 1050 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005757-g004">Fig. 4C and D</xref>
###xml 141 147 <span type="species:ncbi:9606">humans</span>
###xml 160 164 <span type="species:ncbi:10090">Mice</span>
We then studied CDDO-MA in a chronic paradigm of MPTP-toxicity. The chronic MPTP model better mimics the neuropathological features of PD in humans [31], [32]. Mice were pre-treated with either CDDO-MA or control diet. Seven days later animals received a continuous infusion of MPTP (40 mg/kg/day for 28 days) or sodium phosphate-buffered saline (PBS) by subcutaneous implantation of mini-osmotic pumps. Animals were administered either CDDO-MA or control diet through out the duration of the osmotic pumps. After 28 days, there was a significant reduction (about 50%) in total striatal dopamine and also its metabolites, DOPAC and HVA. CDDO-MA treatment significantly protected against MPTP-induced striatal depletion of dopamine and its metabolites (Table 1) (ANOVA p<0.05). Immunohistochemical analysis of the SNpc after 28 days showed a marked reduction of total (Nissl positive) and TH-immunoreactive neurons following MPTP. CDDO-MA treatment significantly protected against MPTP-induced loss of TH-immunoreactive and total neurons of the SNpc (Fig. 4C and D) (ANOVA, p<0.05).
###end p 29
###begin p 30
###xml 195 196 195 196 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 334 338 <span type="species:ncbi:10090">mice</span>
The neuroprotective effects provided by CDDO-MA treatment following MPTP-neurotoxicity were not due to impairment of the metabolism of MPTP, since the striatal tissue levels of its metabolite MPP+ (1-methyl-4-phenyl-pyridinium ion) showed no differences between the control (9.85+/-0.69 ng/mg protein, n = 13) and the CDDO-MA treated mice (9.83+/-0.50 ng/mg protein, n = 15), when measured after 28 days of chronic treatment of MPTP (40 mg/kg/day for 28 days).
###end p 30
###begin title 31
CDDO-MA blocks MPTP-induced lipid peroxidation and alpha-synuclein accumulation
###end title 31
###begin p 32
###xml 346 353 338 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005757-g004">Fig. 4E</xref>
###xml 447 454 435 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005757-g004">Fig. 4F</xref>
###xml 786 799 762 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005757-g004">Fig. 4E and F</xref>
In order to determine if neuroprotective effects of CDDO-MA can block MPTP-induced oxidative damage and increase in alpha-synuclein accumulation we examined malondialdehyde and alpha-synuclein immunostaining in SNpc. Chronic administration of MPTP resulted in a marked induction of oxidative damage as measured by malondialdehyde immunostaining (Fig. 4E), and caused a marked increase in alpha-synuclein accumulation in SNpc dopaminergic neurons (Fig. 4F). MPTP-induced alpha-synuclein accumulation was observed in TH-positive neurons of SNpc as determined by colocalization of alpha-synuclein- and TH-immunostaining employing confocal microscopy (data not shown). Treatment with CDDO-MA blocked MPTP-induced mesencephalic malondialdehyde formation and accumulation of alpha-synuclein (Fig. 4E and F). These data show that CDDO-MA produces neuroprotective effects by reducing oxidative stress. It also reduces alpha-synuclein accumulation in the SNpc.
###end p 32
###begin title 33
CDDO-MA blocks 3-nitropropionic acid-induced striatal toxicity
###end title 33
###begin p 34
###xml 160 164 160 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Beal1">[33]</xref>
###xml 732 738 732 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005757-g005">Fig 5A</xref>
###xml 874 881 874 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005757-g005">Fig. 5B</xref>
###xml 172 176 <span type="species:ncbi:10116">rats</span>
3-Nitropropionic acid (3-NP) administration in rodents is known to cause striatal degeneration known to replicate pathological features of Huntington's disease [33]. Lewis rats were pretreated either with CDDO-MA (800 mg/kg of diet) or control diet for one week. 3-NP (50 mg/kg/day for 7 days) or PBS was delivered chronically by subcutaneous implantation of mini-osmotic pumps. Animals were treated with either CDDO-MA or control diet throughout the administration of 3-NP. Analysis of striatal neurons by neuron-specific nuclear protein (NeuN) immunohistochemistry after 3-NP administration showed a profound loss of striatal neurons. CDDO-MA treatment significantly attenuated 3-NP-induced loss of striatal NeuN stained neurons (Fig 5A). Quantitative assessment showed that 3-NP induced striatal lesion volumes were reduced by more than 70% by administration of CDDO-MA (Fig. 5B) (p<0.01).
###end p 34
###begin title 35
CDDO-MA reduces striatal damage caused by 3-NP toxicity, and blocks 3-NP induced striatal glutathione depletion.
###end title 35
###begin p 36
###xml 216 218 216 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A.</italic>
###xml 753 755 753 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B.</italic>
###xml 1081 1082 1079 1080 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1160 1161 1158 1159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 1191 1193 1189 1191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C.</italic>
###xml 1789 1790 1785 1786 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1847 1848 1843 1844 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">#</sup>
###xml 1848 1849 1844 1845 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 6 10 <span type="species:ncbi:10116">rats</span>
###xml 321 325 <span type="species:ncbi:10116">rats</span>
###xml 1175 1179 <span type="species:ncbi:10116">rats</span>
###xml 1194 1198 <span type="species:ncbi:10116">Rats</span>
###xml 1900 1904 <span type="species:ncbi:10116">rats</span>
Lewis rats were pre-treated with either CDDO-MA diet (800 mg/kg) or control diet 7 days followed by continuous infusion of 3-NP (50 mg/kg/day) delivered through subcutaneously implanted miniosmotic pumps for 7 days. A. Photomicrographs of NeuN-immunostained sections through the coronal section of striatum and cortex of rats treated with control diet+PBS (left), control diet with 3-NP (middle) and CDDO-MA diet with 3-NP (right) show a significant loss of NeuN positive cells in 3-NP treated cortex and caudate compared to PBS controls. CDDO-MA treatment significantly reduced 3-NP induced loss of cortical and caudate NeuN positive cells. High magnifications in lower panel show the striatal neuronal loss caused by 3-NP and preservation by CDDO-MA. B. Consistent with loss of NeuN positive cells in cortex and the caudate, measurement of lesion volume in coronal brain slices of 3-NP treated controls show a significant increase in striatal lesion volumes. The administration of CDDO-MA significantly reduces striatal lesion volumes caused by 3-NP. Data represent mean+/-SEM. *p<0.01, statistical significance compared to 3-NP treated controls, by student-t test, n = 15 rats per group. C. Rats described above were also used for analysis of striatal levels of reduced and oxidized glutathione. 3-NP administration resulted in a statistically significant reduction of striatal levels of reduced glutathione (GSH) and the ratio of reduced and oxidized glutathione (GSH/GSSG), whereas levels of oxidized glutathione (GSSG) were not significantly affected by 3-NP treatment measured by HPLC-electrochemistry. CDDO-MA treatment significantly blocked 3-NP induced reductions in striatal levels of GSH and the ratio of GSH/GSSG without impacting the GSSG levels. Data represent mean+/-SEM. *p<0.05, statistical significance compared to controls and #p<0.05 compared to 3-NP treatment, by ANOVA, n = 10 rats per group.
###end p 36
###begin title 37
CDDO-MA preserves 3-NP-induced impairment of striatal glutathione homeostasis, and blocks oxidative damages
###end title 37
###begin p 38
###xml 139 143 139 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Klivenyi1">[34]</xref>
###xml 568 575 568 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005757-g005">Fig. 5C</xref>
###xml 159 163 <span type="species:ncbi:10116">rats</span>
Striatal degeneration caused by 3-NP administration in rodents induces oxidative damage, especially alterations in glutathione homeostasis [34]. We pretreated rats either with CDDO-MA (800 mg/kg of diet) or control diet for one week followed by mini-osmotic pump delivery of 3-NP (50 mg/kg/day for 7 days). Administration of 3-NP resulted in a significant reduction of reduced glutathione (GSH), and the ratio of reduced to oxidized glutathione (GSH/GSSG). Treatment with CDDO-MA significantly blocked 3-NP-induced depletion of striatal GSH and the ratio of GSH/GSSG (Fig. 5C).
###end p 38
###begin p 39
###xml 205 212 205 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005757-g006">Fig. 6A</xref>
###xml 543 550 543 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005757-g006">Fig. 6B</xref>
###xml 554 555 554 555 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 707 708 707 708 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 723 730 723 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005757-g006">Fig. 6C</xref>
###xml 965 972 965 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005757-g006">Fig. 6D</xref>
###xml 1178 1185 1178 1185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005757-g006">Fig. 6E</xref>
###xml 1269 1273 <span type="species:ncbi:10116">rats</span>
Immunohistochemical analysis of striatal slices after 3-NP showed a marked increase in malondialdehyde staining. CDDO-MA treatment completely blocked 3-NP induced malondialdehyde staining in the striatum (Fig. 6A). Quantitative measurement of malondialdehyde by high-performance liquid chromatography (HPLC) revealed a significant increase of malondialdehyde both in striatum and cerebral cortex following 3-NP treatment. 3-NP induced elevations of malondialdehyde levels in these two areas were significantly attenuated by CDDO-MA treatment (Fig. 6B). F2-Isoprostanes, a marker of lipid peroxidation, showed a marked increase after 3-NP treatment. CDDO-MA significantly blocked 3-NP induced generation of F2-Isoprostanes (Fig. 6C). Furthermore, administration of 3-NP resulted in DNA oxidation as measured by the ratio of 8-hydroxy-2-deoxyguanosine (8OH2dG)/deoxyguanosine (dG) in the cerebral cortex, which was significantly attenuated by CDDO-MA administration (Fig. 6D). 3-NP administration produced a profound increase in striatal immunostaining of 3-nitrotyrosine, a nitrated tyrosine marker for protein oxidation, which was markedly attenuated by treatment with CDDO-MA (Fig. 6E). These results suggest that CDDO-MA blocks oxidative damage seen in 3-NP model in rats.
###end p 39
###begin title 40
CDDO-MA treatment blocks 3-NP induced oxidative damage.
###end title 40
###begin p 41
###xml 24 32 24 32 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005757-g004">figure 4</xref>
###xml 110 112 110 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A.</italic>
###xml 413 415 409 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B.</italic>
###xml 728 729 722 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 767 768 761 762 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">#</sup>
###xml 768 769 762 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 836 838 830 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C.</italic>
###xml 901 902 895 896 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 918 919 912 913 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1007 1008 1001 1002 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1101 1102 1095 1096 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1145 1146 1137 1138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1184 1185 1176 1177 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">#</sup>
###xml 1185 1186 1177 1178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1253 1255 1245 1247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D.</italic>
###xml 1511 1512 1501 1502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1550 1551 1540 1541 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">#</sup>
###xml 1551 1552 1541 1542 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1619 1621 1609 1611 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E.</italic>
###xml 6 10 <span type="species:ncbi:10116">rats</span>
###xml 205 209 <span type="species:ncbi:10116">rats</span>
###xml 375 379 <span type="species:ncbi:10090">mice</span>
###xml 820 824 <span type="species:ncbi:10116">rats</span>
###xml 951 955 <span type="species:ncbi:10116">rats</span>
###xml 1237 1241 <span type="species:ncbi:10116">rats</span>
###xml 1603 1607 <span type="species:ncbi:10116">rats</span>
###xml 1719 1723 <span type="species:ncbi:10116">rats</span>
###xml 1957 1961 <span type="species:ncbi:10116">rats</span>
Lewis rats described in figure 4 were also used for striatal and cortical levels of oxidative damage markers. A. Photomicrographs of malondialdehyde (MDA)-immunostained coronal sections of the striatum of rats administered with 3-NP shows an increase in MDA staining in striatum. Treatment with CDDO-MA markedly reduced 3-NP induced MDA immunostaining in the striatum, n = 5 mice per group, scale bar: 100 microm B. Consistent with the striatal immunostaining of MDA, HPLC-electrochemical analysis of MDA levels in striatum and cortex show 3-NP resulted in a statistically significant increase in MDA levels. CDDO-MA treatment significantly reduced 3-NP induced MDA formation in striatum and cortex. Data represent mean+/-SEM. *p<0.05 compared to normal controls and #p<0.05 compared to 3-NP treatment, by ANOVA, n = 10 rats per group. C. Gas chromatography/Mass spectrometric analysis of esterified F2-Isoprostanes (F2-IsoPs) in cerebral cortex from rats treated with 3-NP showed significant increases in F2-IsoPs levels. CDDO-MA treatment significantly abrogated 3-NP induced cortical increases in F2-IsoPs levels. Data represent mean+/-SEM. *p<0.05 compared to normal controls and #p<0.05 compared to 3-NP treatment, by ANOVA, n = 10 rats per group. D. HPLC-electrochemical analysis of the ratio of 8OH2dG over dG shows a significant increase in oxidative DNA damage in the cerebral cortex following 3-NP treatment which is significantly attenuated due to CDDO-MA administration. Data represent mean+/-SEM. *p<0.05 compared to normal controls and #p<0.05 compared to 3-NP treatment, by ANOVA, n = 10 rats per group. E. Photomicrographs of 3-nitrotyrosine-immunostained coronal brain sections through the striatum of rats show a significant elevation in 3-nitrotyrosine levels (a marker of protein nitration) due to 3-NP administration. Treatment of CDDO-MA significantly reduced 3-NP induced increase in immunostaining of striatal 3-nitrotyrosine, n = 5 rats per group, scale bar: 100 microm.
###end p 41
###begin p 42
Overall, our results show that CDDO-MA is a selective and potent activator of the Nrf2/ARE signaling pathway and activation of this pathway provides neuroprotective effects in experimental models of PD and HD.
###end p 42
###begin title 43
Discussion
###end title 43
###begin p 44
###xml 106 109 106 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Lee1">[3]</xref>
###xml 110 113 110 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Thomas1">[5]</xref>
A promising pathway for neurotherapeutics in neurodegenerative diseases is the Nrf2/ARE signaling pathway [3]-[5]. The ability to induce neuroprotective phase 2 detoxifying genes, as well as antioxidant enzymes at transcriptional level, could have significant advantages over more conventional approaches. One can potentially induce an ongoing neuroprotective response which would not be dependent on the antioxidant effects of single molecules, which are frequently consumed while scavenging reactive oxygen species (ROS).
###end p 44
###begin p 45
###xml 220 223 220 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Holtzclaw1">[7]</xref>
###xml 225 228 225 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Kobayashi1">[8]</xref>
###xml 230 234 230 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Eggler1">[10]</xref>
###xml 526 529 526 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Lee1">[3]</xref>
###xml 735 738 735 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Lee1">[3]</xref>
###xml 740 744 740 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Kwak1">[13]</xref>
###xml 1198 1202 1198 1202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Liberatore1">[17]</xref>
###xml 1204 1208 1204 1208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Klivenyi2">[35]</xref>
###xml 1209 1213 1209 1213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Kiaei1">[38]</xref>
Under basal conditions, Nrf2 is anchored in the cytoplasm to the actin bound protein KEAP1. In response to oxidative stress Nrf2 is released from the KEAP1/Nrf2 complex and then activates ARE-mediated gene transcription [7], [8], [10]. Genes known to have ARE response elements include glutathione-S-transferases, NQO-1, HO-1, thioredoxin, and enzymes involved in glutathione synthesis. A number of other genes are also under the regulatory control of Nrf2/ARE signaling which are involved in immune function and inflammation [3]. Furthermore, a number of growth factors including nerve growth factor, fibroblast growth factor, and brain derived neurotrophic factor are induced in primary neurons by activation of the Nrf2/ARE pathway [3], [13]. Additionally, a number of enzymes involved in glycolytic metabolism, as well as heat shock proteins, and ferritin light and heavy chains are also induced. Of particular interest are iNOS and COX-2 which are downregulated due to activation of Nrf2 signaling. These pro-inflammatory genes have been implicated in inflammatory pathways involved in a number of neurodegenerative diseases including PD, Alzheimer's disease and amyotrophic lateral sclerosis [17], [35]-[38].
###end p 45
###begin p 46
###xml 252 256 252 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Liby1">[12]</xref>
###xml 789 793 789 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Liby1">[12]</xref>
###xml 1226 1230 1219 1223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Liby1">[12]</xref>
###xml 2000 2004 1993 1997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Shih1">[20]</xref>
###xml 2969 2972 2962 2965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-DinkovaKostova1">[9]</xref>
###xml 2974 2978 2967 2971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Liby2">[26]</xref>
###xml 2980 2984 2973 2977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Thimmulappa1">[28]</xref>
###xml 395 401 <span type="species:ncbi:9606">humans</span>
###xml 1254 1259 <span type="species:ncbi:9606">human</span>
###xml 2180 2185 <span type="species:ncbi:10090">mouse</span>
###xml 2236 2240 <span type="species:ncbi:10090">mice</span>
###xml 2446 2450 <span type="species:ncbi:10090">mice</span>
Thus pharmacological agents that have the ability to activate the Nrf2/ARE signaling pathway hold great promise for therapeutic intervention in neurodegenerative diseases. One such class of compounds known to activate this pathway is the triterpenoids [12]. Triterpenoids are synthesized by the cyclization of squalene, a triterpene hydrocarbon found ubiquitously in nature including plants and humans. More than 20,000 triterpenoids are known to occur in nature of which oleanolic acid has been used for centuries in traditional Asian medicine, due to its anti-inflammatory activity. Using an assay for iNOS, a derivative of oleanolic acid CDDO (2-cyano-3, 12-dioxooleana-1,9-dien-28-oic acid) was identified that is over 200,000 times more active than its parent molecule oleanolic acid [12]. Structure-activity analysis shows that alpha, beta-unsaturated carbonyl groups in CDDO at key positions on rings A and C are essential for enabling Michael addition with a nucleophilic target similar to Keap 1 (a protein with multiple nucleophilic -SH residues and a cytoplasmic repressor of Nrf2). This reaction activates the phase 2 responses, an intrinsic mechanism used by cells to deactivate electrophiles or oxidative stress [12]. In the present study, human neuroblastoma cells treated by CDDO-MA demonstrated a stream of changes in the phase 2 response through Nrf2/ARE pathway activation. These include induction of Nrf2 protein levels and subsequent nuclear translocation from the cytosol. The nuclear translocation of Nrf2 resulted in induction of phase 2 genes encoding a coordinated family of cytoprotective proteins that include the enzymes of glutathione synthesis and transfer, the quinone oxidoreductase NQO-1, and the hemeoxygenase HO-1. Significantly, the phase 2 response in neuroblastoma cells due to CDDO-MA was translated functionally by a dose dependent increase in cellular GSH production, one of the major cellular antioxidants under the regulatory control of Nrf2/ARE signaling [20]. Another significant finding in our study is that the phase 2 response due to Nrf2/ARE activation by CDDO-MA is selective and depends on the presence of a functional Nrf2. In mouse embryonic fibroblast cells derived from wild type mice CDDO-MA treatment resulted in induction of mRNA levels for ARE genes such as GSTa3, NQO-1 and HO-1. The induction of these ARE genes was completely absent in embryonic fibroblasts cells from Nrf2 knockout mice. This effect was consistent with the dose-dependent reduction of t-butylhydroperoxide-induced ROS in wild type but not Nrf2 knockout fibroblast cells. It is thus plausible that CDDO-MA may very well enable Michael's addition to its target Keap1 which is the cytosolic repressor of Nrf2, since induction of ARE genes require presence of functional Nrf2 and its translocation from cytosol to nucleus. Previously, the ability of synthetic triterpenoids to activate the ARE pathway in other model systems was demonstrated [9], [26], [28]. However, our results in the present study for the first time have shown that synthetic triterpenoids such as CDDO-MA are potent inducers of Nrf2 expression, and activators of the ARE pathway in a neuronal cell line.
###end p 46
###begin p 47
###xml 9 17 9 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 248 249 248 249 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 269 273 269 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Lee2">[19]</xref>
###xml 416 420 416 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Calkins2">[21]</xref>
###xml 755 759 755 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Chen1">[22]</xref>
###xml 761 765 761 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Vargas1">[23]</xref>
###xml 864 871 864 871 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1478 1482 1478 1482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Burton1">[39]</xref>
###xml 1991 1995 1983 1987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Fornai1">[31]</xref>
###xml 1997 2001 1989 1993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Thomas2">[32]</xref>
###xml 2003 2007 1995 1999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Betarbet1">[40]</xref>
###xml 2009 2013 2001 2005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-ManningBog1">[41]</xref>
###xml 2097 2101 2085 2089 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Fornai1">[31]</xref>
###xml 2103 2107 2091 2095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Klivenyi3">[42]</xref>
###xml 2273 2277 2257 2261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Martin2">[43]</xref>
###xml 2279 2283 2263 2267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Norris1">[44]</xref>
###xml 2477 2481 2457 2461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Trinh1">[45]</xref>
###xml 83 87 <span type="species:ncbi:10090">mice</span>
###xml 303 307 <span type="species:ncbi:10090">mice</span>
###xml 589 604 <span type="species:ncbi:10090">transgenic mice</span>
###xml 737 742 <span type="species:ncbi:10090">mouse</span>
###xml 986 990 <span type="species:ncbi:10090">mice</span>
###xml 1364 1368 <span type="species:ncbi:10090">mice</span>
###xml 2030 2034 <span type="species:ncbi:10090">mice</span>
###xml 2116 2121 <span type="species:ncbi:9606">human</span>
###xml 2158 2162 <span type="species:ncbi:10090">mice</span>
Previous in vitro studies showed that neuronal cultures derived from Nrf2 knockout mice have increased susceptibility to oxidative stress, as well as damage produced by mitochondrial electron transport chain complex inhibitors such as rotenone, MPP+, 3-NP and malonate [19]. Furthermore, Nrf2 deficient mice show profound susceptibility to striatal lesions produced by the mitochondrial complex 2 inhibitor malonate [21]. Conversely, the implantation of intrastriatal grafts of astrocytes overexpressing Nrf2, produced neuroprotection against the neurotoxic effects of malonate. Recently, transgenic mice overexpressing Nrf2 in astrocytes were shown to be resistant to MPTP toxicity and to extend survival when crossed with a transgenic mouse mode of ALS [22], [23]. In order to study the neuroprotective efficacy of CDDO-MA induced activation of Nrf2/ARE pathway in vivo we used two neurotoxic paradigms of MPTP, involving acute 7-day and chronic continuous infusion for four weeks in mice. Administration of CDDO-MA produced significant neuroprotection against loss of striatal dopamine and its metabolites. Furthermore, it produced significant protection against loss of tyrosine hydroxylase immunoreactive neurons in the SNpc. These data are consistent with MPTP-induced enhanced susceptibility to nigrostriatal dopaminergic neurodegeneration in Nrf2 knockout mice, suggesting that impairment of Nrf2/ARE signaling is an important mediator of dopaminergic neurodegeneration [39]. Additionally, in the chronic MPTP neurotoxicity paradigm, there was increased accumulation of alpha-synuclein (a neuropathological feature seen in PD) in dopaminergic neurons, which was blocked by administration of CDDO-MA. This is consistent with other reports where chronic administration of MPTP, and other toxins which specifically target mitochondria such as rotenone and paraquat, produce mitochondrial dysfunction leading to oxidative stress resulting in alpha-synuclein accumulation in SNpc neurons [31], [32], [40], [41]. Interestingly, mice lacking alpha-synuclein are resistant to mitochondrial toxins [31], [42] whereas human A53T alpha-synuclein-overexpressing mice are known to develop neuronal mitochondrial degeneration and cell death through induction of oxidative stress [43], [44]. This notion gains support from a recent study where activation of phase 2 detoxification enzymes blocked oxidative stress induced dopaminergic neurodegeneration in a alpha-synuclein fly model [45]. Notably, in our studies chronic MPTP-induced oxidative damage in SNpc neurons as measured by malondialdehyde staining was markedly blocked by CDDO-MA administration. This effect of CDDO-MA is consistent with its ability to activate ARE genes in fibroblasts to scavenge t-butylhydroperoxide induced ROS generation.
###end p 47
###begin p 48
###xml 95 99 95 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Shih1">[20]</xref>
###xml 246 253 246 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 253 257 253 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Shih1">[20]</xref>
###xml 421 425 421 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Shih1">[20]</xref>
###xml 623 627 623 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Ouary1">[46]</xref>
###xml 1053 1054 1053 1054 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1070 1071 1070 1071 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1141 1142 1141 1142 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1258 1262 1258 1262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Milne1">[47]</xref>
###xml 1264 1268 1264 1268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Montine1">[48]</xref>
###xml 1290 1291 1290 1291 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1367 1374 1367 1374 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1427 1428 1427 1428 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1494 1498 1494 1498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Montine1">[48]</xref>
###xml 1531 1535 1531 1535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Montine2">[49]</xref>
###xml 54 58 <span type="species:ncbi:10090">mice</span>
###xml 384 388 <span type="species:ncbi:10090">mice</span>
###xml 416 420 <span type="species:ncbi:10090">mice</span>
###xml 618 622 <span type="species:ncbi:10116">rats</span>
Previous reports have demonstrated that Nrf2 knockout mice are more sensitive to 3-NP toxicity [20]. In cultured astrocytes, 3-NP increases Nrf2 activity, which may account for the increased sensitivity of Nrf2 deficient animals to 3-NP toxicity in vivo[20]. Additionally, dietary supplementation with the Nrf2 inducer tertbutylhydroquinone attenuated 3-NP toxicity in Nrf2 competent mice, but not in Nrf2 deficient mice [20]. To further demonstrate that activation of Nrf2/ARE pathway by CDDO-MA could be beneficial in a rodent model of 3-NP mediated HD, we employed systemic administration of 3-NP toxicity in Lewis rats [46]. Our findings demonstrate that administration of CDDO-MA reduced the striatal lesion volumes by more than 70%. Histological evaluation confirmed that CDDO-MA significantly protects against 3-NP induced neuronal death. Additionally, we observed that CDDO-MA blocked 3-NP induced increases in 8-hydroxy-2-deoxyguanosine, a marker of oxidative damage to DNA, and malondialdehyde levels in the striatum and cortex. Increases in F2-Isoprostanes (F2-IsoPs) in cerebral cortex produced by 3-NP were blocked by CDDO-MA. F2-Isoprostanes are prostaglandin-like lipids derived from the free-radical mediated peroxidation of arachidonic acid [47], [48]. The measurement of F2-IsoPs by GC/MS is considered the most accurate index of lipid peroxidation in vivo, and elevated levels of tissue-esterified and free F2-IsoPs have been described in numerous neurodegenerative diseases [48], including Huntington's disease [49].
###end p 48
###begin p 49
###xml 693 700 693 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 721 725 721 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Shih1">[20]</xref>
###xml 908 916 908 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 916 919 916 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Lee1">[3]</xref>
###xml 921 925 921 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Calkins2">[21]</xref>
###xml 927 931 927 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Kraft1">[50]</xref>
###xml 1347 1351 1347 1351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Vargas1">[23]</xref>
###xml 1416 1424 1416 1424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1475 1482 1475 1482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1691 1699 1691 1699 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo,</italic>
###xml 1150 1165 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1212 1216 <span type="species:ncbi:10090">mice</span>
###xml 1250 1255 <span type="species:ncbi:10090">mouse</span>
Increases in 3-NP induced immunostaining for malondialdehyde and 3-nitrotyrosine, a marker of protein nitration, were blocked by CDDO-MA administration. Furthermore, increased production of glutathione, due to induction of glutathione synthetic enzymes is a well known effect of increased expression of the Nrf2/ARE genes. We found that administration of 3-NP significantly reduced striatal concentrations of reduced glutathione (GSH), and the reduction in GSH and the ratio of GSH/GSSG were completely prevented by CDDO-MA administration. This is consistent with adenoviral overexpression of Nrf2 in the striatum, which mainly infects astrocytes, which was sufficient to reduce 3-NP toxicity in vivo by synthesis of GSH [20]. This view is further strengthened when only a small number of Nrf2 expressing astrocytes can confer neuroprotection to many neighboring neurons during an oxidative glutamate insult in vitro[3], [21], [50]. These Nrf2 overexpressing astrocytes secrete high levels of glutathione, providing a means for a small number of astrocytes to affect the survival of a much larger number of neurons. Similar observations were made in transgenic mice overexpressing Nrf2 in astrocytes. When these mice were crossed with two transgenic mouse models of familial amyotrophic lateral sclerosis, they delayed onset and extended survival [23]. Motor neuron protection was dependent on glutathione secretion in vitro and spinal cord glutathione levels were increased in vivo. Our results demonstrating a dose-dependent increase of cellular GSH levels in neuroblastoma cells following CDDO-MA treatment, also suggests that CDDO-MA not only impacts glutathione synthesis in astrocytes in vivo, but also may activate inherent neuronal GSH synthesis to provide neuroprotection against 3-NP neurotoxicity.
###end p 49
###begin p 50
###xml 307 311 304 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Dumont1">[51]</xref>
###xml 272 277 <span type="species:ncbi:10090">mouse</span>
###xml 1118 1126 <span type="species:ncbi:9606">patients</span>
In summary the present study demonstrates that CDDO-MA is a potent activator of Nrf2/ARE signaling pathway and renders neuroprotection against MPTP and 3-NP neurotoxicity. We recently showed that CDDO-MA reduces beta-amyloid deposition and improves memory in a transgenic mouse model of Alzheimer's disease [51]. In that study we showed that administration of CDDO-MA increased brain levels of HO-1, an Nrf2/ARE dependent enzyme. These results provide compelling evidence for the utility of pharmacological agents known to activate Nrf2/ARE mediated phase 2 detoxification genes for the treatment of neurodegenerative diseases. Currently the parent compound, CDDO, and its close relative, CDDO-methyl ester, are in Phase I studies for the treatment of cancer. For applications in neurodegenerative disease, the superior pharmacokinetics of CDDO-MA in the brain provides a rationale for further investigation of this agent, as well as related triterpenoid amides. Our data provide a strong rationale for further preclinical investigation of CDDO-MA and other related amides, directed toward eventual clinical trials in patients with Parkinson's and Huntington's disease.
###end p 50
###begin title 51
Materials and Methods
###end title 51
###begin title 52
Cell Culture studies
###end title 52
###begin p 53
###xml 205 206 195 196 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 689 693 675 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Thomas2">[32]</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human neuroblastoma SH-SY5Y cells (ATCC, Manassas, VA) were cultured in DMEM supplemented with 10% FBS, 100 U/ml penicillin, and 100 microg/ml streptomycin at 37degreesC in a humidified atmosphere of 5% CO2. Cells were cultured up to 80-90% confluency in 10 cm dishes for real time PCR, western blotting and measurement of GSH and GSSG. For western blot analysis cells were harvested in lysis buffer (50 mm Tris-HCl, pH 7.4, 150 mm NaCl, 5 mm EDTA, 1% sodium dodecyl sulfate (SDS)) supplemented with the protease inhibitor cocktail (EDTA-free, Roche) and a phosphatase inhibitor cocktail (Sigma). Ten microg of the total protein were subjected to immunoblot analyses by a described method [32] using appropriate primary antibodies (anti-Nrf2, (1:1000 Epitomics CA); anti-NQO1, anti-glutathione reductase and anti-heme oxygenase-1 (1:1000 Abcam MA) and anti-beta-actin Chemicon 1:10,000)). Densitometric analyses were performed using the NIH Image J Software.
###end p 53
###begin p 54
###xml 80 82 80 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 378 382 <span type="species:ncbi:9925">goat</span>
###xml 486 492 <span type="species:ncbi:9986">rabbit</span>
###xml 643 649 <span type="species:ncbi:9986">rabbit</span>
Nrf2 immunostaining was performed in SH-SY5Y cells cultured at a density of 1x10-6 cells/ml in 4 well chamber slides (BD Biosciences CA). Cells were fixed at room temperature with 2% paraformaldehyde in phosphate buffered saline (PBS), washed three times in PBS for 5 min, and permeabilized with 0.1% TritonX-100 in PBS. Non-specific antibody binding was blocked with 5% normal goat serum (NGS) in PBS for 1 h at room temperature. Then, cells were incubated overnight at 4degreesC with rabbit monoclonal anti-Nrf2 antibody (1:200 in PBS plus 1.5% NGS, Epitomics CA), washed three times with PBS, and further incubated with Cy3-conjugated anti-rabbit IgG (1:500 in PBS plus 0.1% NGS, Jackson Immunoresearch, PA) for 2 h at room temperature. They were washed in PBS three times for 5 minutes each at room temperature and incubated with 4',6-diamidino-2-phenylindole, dilactate (DAPI, dilactate) (1:1000, Invitrogen, Carlsbad, CA) for 10 minutes and rinsed in distilled water, air dried and cover slipped using immumount mounting media (Thermo Shandon, Pittsburg, PA). For microscopic analysis, the sections were visualized using a Zeiss Confocal microscope (LSM 510 Meta) (Carl Zeiss Vision, Hallbergmoos, Germany) equipped with an argon laser. DAPI immunofluorescence was given a pseudo green color in order to demonstrate a clear contrast for Nrf2 co-localization with nuclear stain DAPI following CDDO-MA treatment.
###end p 54
###begin title 55
RNA isolation and real-time RT-PCR
###end title 55
###begin p 56
###xml 421 425 421 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Holland1">[52]</xref>
###xml 549 553 541 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Livak1">[53]</xref>
###xml 27 32 <span type="species:ncbi:10090">mouse</span>
Total RNA from SH-SY5Y and mouse embryonic fibroblast cells were isolated according to manufacturer's protocol using TRIzol reagent (Invitrogen CA). Total RNA purity and integrity was confirmed by ND-1000 NanoDrop (NanoDrop Technologies) and 2100 Bioanalyzer (Agilent). Real-time PCR was performed using the ABI prism 7900 HT sequence detection system (Applied Biosystems, Foster City, CA) based on the 5'-nuclease assay [52] for various genes indicated and housekeeping gene GAPDH. Relative expression was calculated using the DeltaDelta Ct method [53].
###end p 56
###begin title 57
###xml 42 47 <span type="species:ncbi:10090">mouse</span>
Measurement of reactive oxygen species in mouse embryonic fibroblasts
###end title 57
###begin p 58
###xml 154 155 150 151 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 28 33 <span type="species:ncbi:10090">mouse</span>
Wild type and Nrf2 knockout mouse embryonic fibroblasts were treated with CDDO-MA for 18 hours and incubated with 10 micromol/L nonfluorescent indicator H2DCFDA (2', 7'-Dichlorodihydrofluorescein diacetate, Invitrogen CA) for 30 minutes. Cells were challenged with 250 micromol/L tert-butyl hydroperoxide (tBHP) for 15 minutes, and mean fluorescence intensity of 10,000 cells was analyzed by FACScan flow cytometry (Becton Dickinson, NJ) using a 480-nm excitation wavelength and a 525-nm emission wavelength.
###end p 58
###begin title 59
Animals and materials
###end title 59
###begin p 60
###xml 379 383 379 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Honda1">[25]</xref>
###xml 13 17 <span type="species:ncbi:10090">mice</span>
###xml 56 60 <span type="species:ncbi:10116">rats</span>
Male C57BL/6 mice (3-month old, 25-30 g) and male Lewis rats (3-month old, 250-300 g) were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). Neurotoxins MPTP and 3NP, neurochemicals dopamine, DOPAC and HVA, and malondialdehyde (MDA) were all purchased from Sigma (St. Louis, MO, USA). CDDO-MA was synthesized by the condensation of methyl amide with CDDO acid chloride [25]. This stable derivative was blended into powdered rodent chow (Lab Diets 5002), after being dissolved in a vehicle comprising of 1 part ethanol/3 parts Neobee Oil (coconut oil triglyceride). For each kg of diet, 800 mg of CDDO-MA was dissolved in 50 ml of the above vehicle before mixing with the chow; the resulting diet was then pelleted for feeding. CDDO-MA is stable (by mass spec analysis) in this feed. All animal experimental procedures were in strict accordance with protocols approved by the Weill Cornell Medical College Institutional Animal Care and Use Committee (IACUC). MPTP and 3-NP manipulations were carried out in a special animal room restricted for neurotoxin manipulation.
###end p 60
###begin title 61
MPTP neurotoxicity paradigms and CDDO-MA treatments
###end title 61
###begin p 62
###xml 97 101 97 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Cleren1">[54]</xref>
###xml 774 775 774 775 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 8 12 <span type="species:ncbi:10090">mice</span>
###xml 352 356 <span type="species:ncbi:10090">mice</span>
###xml 653 657 <span type="species:ncbi:10090">mice</span>
###xml 751 756 <span type="species:ncbi:10090">mouse</span>
C57BL/6 mice were fed with CDDO-MA-containing or control diet for one week before MPTP injection [54]. MPTP-HCl dissolved in PBS was injected intraperitoneally 10 mg/kg, free base for 3 times with an interval of 2 hours. Diets were continued for 7 days after the MPTP injection till they were sacrificed for toxicity analyses. Another group of C57BL/6 mice fed with CDDO-MA-containing or control diet for one week were implanted subcutaneously with osmotic minipumps (Model 2004, Alzet, Cupertino CA, filled with MPTP 170 mg/ml in PBS) that delivered MPTP at a dose of 40 mg/kg body weight daily for 28 day. They were maintained on the same diets. Then mice were sacrificed and tissues were prepared as above except that a piece of striatum from each mouse was saved for MPP+ level measurements.
###end p 62
###begin title 63
###xml 0 3 <span type="species:ncbi:10116">Rat</span>
Rat model of 3-NP toxicity
###end title 63
###begin p 64
###xml 295 299 295 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Ouary1">[46]</xref>
###xml 486 487 486 487 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 503 504 503 504 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 11 15 <span type="species:ncbi:10116">rats</span>
###xml 306 310 <span type="species:ncbi:10116">rats</span>
Male Lewis rats fed with CDDO-MA-containing or control diet for 7 days were implanted subcutaneously with osmotic minipumps (Model 2ML1, Alzet, Cupertino CA, filled with 3-NP 54 mg/ml in PBS, pH 7.4) that delivered 3-NP 50 mg per kg bodyweight daily for 7 days while remaining on the same diets [46]. Then rats were sacrificed and one half of the brain was fixed in 4% paraformaldehyde for the striatal lesion volume measurement and the other half was dissected freshly for GSH, GSSG, F2-Isoprostanes (F2-IsoPs) and MDA assays.
###end p 64
###begin title 65
###xml 40 41 40 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
HPLC analysis for catecholamines and MPP+
###end title 65
###begin p 66
###xml 224 228 224 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Yang1">[55]</xref>
###xml 380 381 380 381 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 383 384 383 384 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 814 815 814 815 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 859 863 859 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Cleren2">[56]</xref>
Striatal levels of dopamine and its metabolites DOPAC and HVA were measured after sonication and centrifugation in chilled 0.1 M perchloric acid (PCA, about 100 ul/mg tissue) as modified from our previously described method [55]. Briefly, 15 ul supernatant was isocratically eluted through an 80x4.6 mm C18 column (ESA, Inc Chelmsford, MA) with a mobile phase containing 0.1 M LiH2PO4, 0.85 mM 1-octanesulfonic acid and 10% (v/v) methanol and detected by a 2-channel Coulochem II electrochemical detector (ESA, Inc. Chelmsford, MA). Concentrations of dopamine, DOPAC and HVA are expressed as ng per mg protein. The protein concentrations of tissue homogenates were measured according to the Bio-Rad protein analysis protocol (Bio-Rad Laboratories, Hercules, CA) and Perkin Elmer Bio Assay Reader (Norwalk, CT). MPP+ was measured according to described method [56].
###end p 66
###begin title 67
HPLC analysis for malondialdehyde
###end title 67
###begin p 68
###xml 92 96 92 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Agarwal1">[57]</xref>
###xml 280 281 268 269 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 283 284 271 272 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 411 412 385 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 542 543 516 517 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 545 546 519 520 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
The determination of malondialdehyde by HPLC was carried out according to a reported method [57]. Briefly, tissues were homogenized in 40% ethanol solution. To a 50-microl aliquot of sample or MDA standard, 50 microl of 0.05% butylated hydroxytoluene (BHT), 400 microl of 0.44 M H3PO4, and 100 microl of 0.42 mM 2-thiobarbituric acid (TBA) were added and heated for 1 h on a 100degreesC, followed by 250 microl n-butanol extraction of the MDA-TBA derivative. The HPLC mobile phase comprised of acetonitrile-buffer (20:80, v/v, buffer 50 mM KH2PO4, pH of 6.8 adjusted with KOH). The column was an ESA 150x3-mm C18 column with particle size of 3 microm (ESA, Inc.). The fluorescence detector was set at an excitation wavelength of 515 nm and emission wavelength of 553 nm. The concentration of MDA is expressed as nmol per mg protein.
###end p 68
###begin title 69
###xml 20 21 20 21 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
GC/MS analysis for F2-Isoprostanes
###end title 69
###begin p 70
###xml 21 22 21 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 38 39 38 39 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 167 168 167 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 169 170 169 170 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 180 186 180 182 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 229 233 225 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Milne1">[47]</xref>
###xml 400 404 396 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Folch1">[58]</xref>
###xml 418 419 414 415 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 516 518 512 514 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">18</sub>
###xml 803 804 799 800 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 860 861 856 857 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 862 863 858 859 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 873 879 869 871 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
Membrane-esterified F2-Isoprostanes (F2-IsoPs) were measured by stable isotope dilution, negative-ion chemical ionization gas chromatography/mass spectrometry using a 4H2-8-iso PGF2alpha internal standard as previously described [47]. Briefly, brain tissue samples were homogenized in 2:1 chloroform:methanol containing 0.5% butylated hydroxytolulene and lipids were extracted by the method of Folch [58]. Esterified F2-IsoPs were hydrolyzed by chemical saponification with 15% potassium hydroxide, extracted using C18 and silica Sep-Pak cartridges (Waters Corporation, Milford, MA), purified by thin-layer chromatography, converted to pentafluorobenzyl ester trimethylsilyl ether derivates, and quantified using gas chromatography/negative ion chemical ionization/mass spectrometry. Quantification of F2-IsoPs was performed by comparison to a known amount of 4H2-8-iso PGF2alpha internal standard.
###end p 70
###begin title 71
HPLC analysis for 8OH2dG and dG
###end title 71
###begin p 72
###xml 78 82 78 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Hofer1">[59]</xref>
###xml 247 248 247 248 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 352 353 344 345 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 517 518 493 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 690 691 662 663 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 693 694 665 666 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 1075 1076 1047 1048 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 93 96 <span type="species:ncbi:10116">rat</span>
DNA extraction and HPLC analysis methods were modified from a previous report [59]. Briefly, rat cortex DNA was extracted using TRIzol reagent (Invitrogen, CA, USA) with the inclusion of 1 mM deferoxamine mesylate (DFOM). DNA pellets in 80 ul of H2O were hydrolyzed by adding 10 microl of Nuclease P1 (0.4 U/microl in 300 mM sodium acetate, 0.2 mM ZnCl2, pH 5.3), and 5 microl of alkaline phosphatase (1 U/microl). The hydrolysate (100 microl) was mixed with 2 microl of 5 M perchloric acid and centrifuged at 18,000 g for enzyme removal. The supernatant (50 microl) was isocratically eluted through a 4.6x250 mm C18 column (ESA, Inc Chelmsford, MA) with a mobile phase containing 20 mM LiH2PO4, 4.0 mM 1-octanesulfonic acid and 1% (v/v) methanol and detected first by a 2-channel Coulochem II electrochemical detector (ESA, Inc. Chelmsford, MA), set with potentials of Channel 1 at 165 mV and Channel 2 at 300 mV for 8OH2dG, and followed by a Waters 486 UV detactor set with a wavelength at 260 nm for dG. DNA oxidation was indicated by the concentration ratio of 8OH2dG x103 vs. dG.
###end p 72
###begin title 73
HPLC analysis for GSH and GSSG
###end title 73
###begin p 74
###xml 188 192 188 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005757-Melnyk1">[60]</xref>
###xml 344 345 344 345 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 347 348 347 348 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
Brain tissues were homogenized while SH-SY5Y cells were sonicated in chilled 0.1 M perchloric acid and centrifuged. The supernatants were taken for HPLC as modified from a reported method [60]. Breifly, 15 ul supernatant was isocratically eluted through a 4.6x150 mm C18 column (ESA, Inc Chelmsford, MA) with a mobile phase containing 50 mM LiH2PO4, 1.0 mM 1-octanesulfonic acid and 1.5% (v/v) methanol and detected by a 2-channel Coulochem III electrochemical detector (ESA, Inc. Chelmsford, MA), set with guard cell potential 950 mV, Channel 1 potential 500 mM for GSH detection and Channel 2 potential 880 mV for GSSG detection. Concentrations of GSH and GSSG are expressed as nmol per mg protein.
###end p 74
###begin title 75
Immunohistochemistry and stereologic analysis
###end title 75
###begin p 76
###xml 329 330 323 324 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 331 332 325 326 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 463 469 <span type="species:ncbi:9913">bovine</span>
###xml 583 589 <span type="species:ncbi:9986">rabbit</span>
###xml 660 666 <span type="species:ncbi:9986">rabbit</span>
###xml 765 771 <span type="species:ncbi:9986">rabbit</span>
###xml 866 871 <span type="species:ncbi:10090">mouse</span>
###xml 948 953 <span type="species:ncbi:10090">mouse</span>
Tissues for histological analysis were fixed with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) and then cryoprotected in 30% sucrose overnight at 4degreesC. A modified avidin-biotin-peroxidase technique was employed for immunohistochemistry. Briefly, 35 micrometer thick coronal brain sections were pretreated with 3% H2O2 in 0.1 M PBS for 30 min. The sections were rinsed in PBS twice for 5 min each. The sections were incubated sequentially in (a) 1% bovine serum albumin (BSA)/0.2% Triton X-100 (Sigma, St. Louis, MO) for 30 minutes, (b) appropriate primary antibodies (rabbit anti-TH affinity purified antibody (1:4,000; Chemicon, Temecula, CA), rabbit immunoaffinity purified anti-nitrotyrosine (4 microg/ml; Upstate Biotechnology, Lake Placid, NY), rabbit polyclonal anti-malondialdehyde (1:1,000; provided by Dr. C. Thomas, Hoechst Marion Roussel), mouse anti-alpha-synuclein (1:1,000; BD Transduction Laboratories, San Jose, CA), mouse anti-NeuN (1:1,000; Chemicon, Temecula, CA)) (diluted in PBS/0.5% BSA) for 18 hours, (c) appropriate biotinylated IgG (1:200, diluted in PBS/0.5% BSA, Vector Laboratories, Burlingame, CA) for 1 hour, and (d) avidin-biotin-peroxidase complex (1:200 in PBS; Vector Laboratories) for 1 hour. The immunoreaction was visualized using 3,3'-diaminobenzidine tetrahydrochloride dihydrate (DAB) with nickel intensification (Vector Laboratories) as the chromogen. All incubations and rinses were performed at room temperature with agitation using an orbital shaker. The sections were mounted onto gelatin-coated slides, dehydrated, cleared in xylene and coverslipped.
###end p 76
###begin p 77
For stereological cell counts serial coronal sections (50 microm) were cut through the substantia nigra using a cryostat. Two sets of sections were prepared with each set consisting of 7-8 sections, 100 microm apart. One set of sections was stained with Nissl (cresyl violet). Another set was processed for TH immunohistochemistry as described above. The numbers of Nissl-stained or TH-immunoreactive neurons in the substantia nigra pars compacta were counted using the optical fractionator method in the Stereo Investigator (v 4.35) software program (Microbrightfield, Burlington, VT).
###end p 77
###begin p 78
A qualitative examination was performed to analyze immunoreactivities of alpha-synuclein, malondialdehyde and nitrotyrosine. The analysis was done using 7 sections per animal (n = 5 per group).
###end p 78
###begin p 79
###xml 68 73 <span type="species:ncbi:10090">mouse</span>
One set of serial sections (210 microm apart) immunostained using a mouse antibody against the neuronal marker NeuN were measured for areas of 3-NP-induced NeuN loss to determine the lesion volume using the point-counting method and the cavalieri principle as estimator in the same software program.
###end p 79
###begin title 80
Statistical analysis
###end title 80
###begin p 81
Data represent mean+/-standard error of means (SEM) from groups of animals. Experimental analysis applied with one-way ANOVA. When F values implied significance at a level p<0.05, Student-Newman-Keul's or Tukey-Kramer multiple comparison tests was applied to determine where the differences among groups arose. All statistical analysis was performed using the Graphpad Instat software (GraphPad, San Diego, CA).
###end p 81
###begin p 82
We thank Beverly J. Lorenzo with technical assistance and Greta Strong, Megan Padgett for assistance with the preparation of this manuscript.
###end p 82
###begin title 83
References
###end title 83
###begin article-title 84
Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases.
###end article-title 84
###begin article-title 85
The energetics of Huntington's disease.
###end article-title 85
###begin article-title 86
Nrf2, a multi-organ protector?
###end article-title 86
###begin article-title 87
The Nrf2-ARE Signalling pathway: promising drug target to combat oxidative stress in neurodegenerative disorders.
###end article-title 87
###begin article-title 88
Parkinson's disease.
###end article-title 88
###begin article-title 89
The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease.
###end article-title 89
###begin article-title 90
Protection against electrophile and oxidative stress by induction of phase 2 genes: the quest for the elusive sensor that responds to inducers.
###end article-title 90
###begin article-title 91
Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species.
###end article-title 91
###begin article-title 92
Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress.
###end article-title 92
###begin article-title 93
###xml 57 62 <span type="species:ncbi:9606">human</span>
Modifying specific cysteines of the electrophile-sensing human Keap1 protein is insufficient to disrupt binding to the Nrf2 domain Neh2.
###end article-title 93
###begin article-title 94
Screening method for the discovery of potential cancer chemoprevention agents based on mass spectrometric detection of alkylated Keap1.
###end article-title 94
###begin article-title 95
Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer.
###end article-title 95
###begin article-title 96
Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival.
###end article-title 96
###begin article-title 97
Bilirubin, formed by activation of heme oxygenase-2, protects neurons against oxidative stress injury.
###end article-title 97
###begin article-title 98
Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications.
###end article-title 98
###begin article-title 99
###xml 15 19 <span type="species:ncbi:10090">mice</span>
Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis.
###end article-title 99
###begin article-title 100
Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease.
###end article-title 100
###begin article-title 101
Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration.
###end article-title 101
###begin article-title 102
NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons.
###end article-title 102
###begin article-title 103
Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo.
###end article-title 103
###begin article-title 104
Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription.
###end article-title 104
###begin article-title 105
###xml 42 47 <span type="species:ncbi:10090">mouse</span>
Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte.
###end article-title 105
###begin article-title 106
###xml 68 73 <span type="species:ncbi:10090">mouse</span>
Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis.
###end article-title 106
###begin article-title 107
A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity.
###end article-title 107
###begin article-title 108
A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production.
###end article-title 108
###begin article-title 109
The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling.
###end article-title 109
###begin article-title 110
Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole.
###end article-title 110
###begin article-title 111
Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-Imidazolide.
###end article-title 111
###begin article-title 112
Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes.
###end article-title 112
###begin article-title 113
Deficiency of the Nrf1 and Nrf2 transcription factors results in early embryonic lethality and severe oxidative stress.
###end article-title 113
###begin article-title 114
Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein.
###end article-title 114
###begin article-title 115
###xml 99 103 <span type="species:ncbi:10090">mice</span>
MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity.
###end article-title 115
###begin article-title 116
Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid.
###end article-title 116
###begin article-title 117
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.
###end article-title 117
###begin article-title 118
###xml 93 98 <span type="species:ncbi:10090">mouse</span>
Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis.
###end article-title 118
###begin article-title 119
###xml 89 104 <span type="species:ncbi:10090">transgenic mice</span>
Motor neuron degeneration in amyotrophic lateral sclerosis mutant superoxide dismutase-1 transgenic mice: mechanisms of mitochondriopathy and cell death.
###end article-title 119
###begin article-title 120
Inflammation in Alzheimer disease: driving force, bystander or beneficial response?
###end article-title 120
###begin article-title 121
###xml 108 113 <span type="species:ncbi:10090">mouse</span>
Integrative role of cPLA with COX-2 and the effect of non-steriodal anti-inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis.
###end article-title 121
###begin article-title 122
In vivo modulation of the Parkinsonian phenotype by Nrf2.
###end article-title 122
###begin article-title 123
Chronic systemic pesticide exposure reproduces features of Parkinson's disease.
###end article-title 123
###begin article-title 124
###xml 82 86 <span type="species:ncbi:10090">mice</span>
The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein.
###end article-title 124
###begin article-title 125
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice lacking alpha-synuclein are resistant to mitochondrial toxins.
###end article-title 125
###begin article-title 126
###xml 36 51 <span type="species:ncbi:10090">transgenic mice</span>
Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death.
###end article-title 126
###begin article-title 127
###xml 75 80 <span type="species:ncbi:10090">mouse</span>
Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model.
###end article-title 127
###begin article-title 128
###xml 75 85 <span type="species:ncbi:7227">Drosophila</span>
Induction of the phase II detoxification pathway suppresses neuron loss in Drosophila models of Parkinson's disease.
###end article-title 128
###begin article-title 129
###xml 124 128 <span type="species:ncbi:10116">rats</span>
Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies.
###end article-title 129
###begin article-title 130
Quantification of F2-isoprostanes as a biomarker of oxidative stress.
###end article-title 130
###begin article-title 131
Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases.
###end article-title 131
###begin article-title 132
Cerebrospinal fluid F2-isoprostanes are elevated in Huntington's disease.
###end article-title 132
###begin article-title 133
Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult.
###end article-title 133
###begin article-title 134
###xml 92 97 <span type="species:ncbi:10090">mouse</span>
Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer's disease.
###end article-title 134
###begin article-title 135
###xml 106 123 <span type="species:ncbi:271">Thermus aquaticus</span>
Detection of specific polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of Thermus aquaticus DNA polymerase.
###end article-title 135
###begin article-title 136
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
###end article-title 136
###begin article-title 137
Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity.
###end article-title 137
###begin article-title 138
A novel azulenyl nitrone antioxidant protects against MPTP and 3-nitropropionic acid neurotoxicities.
###end article-title 138
###begin article-title 139
Promethazine protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.
###end article-title 139
###begin article-title 140
Rapid, fluorimetric-liquid chromatographic determination of malondialdehyde in biological samples.
###end article-title 140
###begin article-title 141
A simple method for the isolation and purification of total lipides from animal tissues.
###end article-title 141
###begin article-title 142
###xml 106 109 <span type="species:ncbi:10116">rat</span>
A method to determine RNA and DNA oxidation simultaneously by HPLC-ECD: greater RNA than DNA oxidation in rat liver after doxorubicin administration.
###end article-title 142
###begin article-title 143
A new HPLC method for the simultaneous determination of oxidized and reduced plasma aminothiols using coulometric electrochemical detection.
###end article-title 143
###begin p 144
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 144
###begin p 145
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: Support for the current study was provided by the Department of Defense, the Michael J. Fox Foundation, NINDS grant NS39258, NCI grant CA 78814, the National Foundation for Cancer Research, and Reata Pharmaceuticals. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 145

